Lynn is currently Non Executive Chair of Zotefoams plc,a FTSE group utilising unique plastic foaming technologies to supply a wide range of industrial and consumer markets. She is also Chair of the Board of Governors and Pro Chancellor of the University of Hertfordshire as well as a NED at the Stevenage Bioscience Catalyst.
Lynn was formerly Non-executive Chair of Venture Life Group, an international consumer healthcare company listed on AIM. She was also Chair of Infirst Healthcare, a privately held consumer healthcare company focused on improving well-established drugs with IP protected solutions for the OTC/primary care markets. Prior to the company being taken over in 2019, she was the Senior Independent Director and Chair of the Remuneration Committee at RPC Group, the FTSE 250 world leading supplier of rigid plastics packaging products and plastic containers.
Other NED roles have included Shield Therapeutics AG, an independent Swiss speciality pharmaceutical company; Consort Medical, a medical technology company; and Allocate Software, a leading workforce optimisation software applications provider for global organisations, prior to its sale to HG Capital. Lynn was also Chair of Breast Cancer Haven, a charity providing personalised care and support to help people through the experience of breast cancer.
In her executive career, Lynn was a Managing Director at Rothschild and her focus was on advising clients within the healthcare sector. Prior to this she worked in the Cabinet Office in London as Private Secretary to the Chief Scientific Advisor. She spent the early part of her career as a research scientist, including a year in Tokyo as a post-doctoral research fellow.
Lynn has a degree in Chemistry from the University of Glasgow and a PhD from the University of London. She is a Fellow of the Royal Society of Edinburgh and a Fellow of the Royal Society of Chemistry.